

# COVID-19 in cancer patients: Effect of primary tumour subtype and patient demographics

L YW Lee<sup>+</sup> (DPhil), JB Cazier<sup>+</sup> (PhD), T Starkey<sup>+</sup> (MSci), S Briggs (BMBCh), R Arnold (PhD), V Bisht (MSc), NA Campton (PhD), VWT Cheng (DPhil), HM Curley (PhD), P Earwaker (DPhil), MW Fittall (PhD), S Gennatas (PhD), A Goel (PhD), S Hartley (PhD), DJ Hughes (MRCP), D Kerr (FMedSci), AJX Lee (PhD), RJ Lee (PhD), H Mckenzie, CP Middleton (PhD), N Murugaesu (PhD), T Newsom-Davis (FRCP), AC Olsson-Brown (MBChB), C Palles (PhD), T Powles (MD) EA Protheroe, K Purshouse (MBBS), A Sharma-Oates (PhD), S Sivakumar (PhD), AJ Smith (MSc), O Topping, C Turnbull (DPhil), C Varnai (PhD), V Woodcock (DPhil), UK Coronavirus Cancer Monitoring Project Team, A. Briggs, Gary Middleton\*, Rachel Kerr\*

**Corresponding Author:** Rachel Kerr, Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, 01865 617331 rachel.kerr@oncology.ac.uk

**\*Joint first Author:** Lennard YW Lee, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. L.lee.2@bham.ac.uk, 0121 414 3511 & Jean-Baptiste Cazier, Centre for Computational Biology, University of Birmingham, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. J.Cazier@bham.ac.uk, 0121 414 6480 & Thomas Starkey, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT,

**\*Joint Senior Author:** Gary Middleton, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. g.middleton@bham.ac.uk, 0121 414 7144 & Rachel Kerr, Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, 01865 617331

**Running Title:** A detailed analysis of risk to cancer patients with COVID-19

**Keywords:** cancer, coronavirus, COVID-19, SARS-CoV-2, United Kingdom, Public Health, subtype, age, demographics

38 Abstract

39

40 *Background*

41 Patients with a diagnosis of cancer are purported to have poor outcomes from COVID-19. However, cancer is a  
42 heterogeneous group of diseases encompassing a wide spectrum of primary tumour subtypes and there have been  
43 no studies evaluating risk from COVID-19 according to cancer subtype and general demographics in the cancer  
44 patient population

45

46 *Methods*

47 A comparison of cancer patients enrolled in the *UK Coronavirus Cancer Monitoring Project (UKCCMP)* and a  
48 parallel non-COVID-19 UK cancer control population cohort was performed, analysing the effect of tumour subtype  
49 and patient demographics (age and sex) on the risk and the trajectory of COVID-19.

50

51 *Findings*

52 In 1,044 patients with COVID-19 enrolled into the UKCCMP we observe that tumour features as well as patient  
53 demographics impact on viral susceptibility and COVID-19 phenotype. SARS-CoV-2 susceptibility is increased in  
54 patients with haematological malignancies (leukaemia/lymphoma/myeloma), and these patients run a more severe  
55 COVID-19 trajectory (OR 1.57, 95% CI 1.15-2.15; p=0.004) and require more intensive clinical support. Case  
56 fatality rate following COVID-19 in patients with leukaemia is increased compared to other cancer types, even  
57 considering other risk factors (OR 2.25, 95% CI [1.13 to 4.57]; p=0.023). Gender and age are the overriding risk  
58 factors for SARS-CoV-2 infection and severity of COVID-19 for most cancer patients, as they are for the general  
59 population.

60

61 *Interpretation*

62 Cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-19 phenotypes. We  
63 have generated individualised risk tables for cancer patients taking into account age/sex and tumour subtype. This  
64 will be useful for physicians to have a more informed risk-benefit discussion to explain COVID-19 risk to their cancer  
65 patients.

66 **Introduction**

67

68 The disease course of individuals contracting SARS-CoV-2 infection is phenotypically diverse. Many patients suffer  
69 only mild symptoms and it is becoming increasingly apparent from antibody data, that others suffer no symptoms  
70 at all but can actively carry and transmit the infection. However, at the other end of the spectrum, some individuals  
71 develop very severe symptoms and can follow an extreme phenotype with the development of respiratory failure,  
72 cytokine release syndrome and multi-organ failure. Subgroups of COVID-19 patients have been identified who  
73 appear to be at increased risk of extreme morbidity and mortality, including patients of advancing age, male gender  
74 (versus female) and those with co-morbidities such as hypertension, chronic lung disease, diabetes and cancer  
75 (1).

76

77 Since COVID-19 started to spread across the globe in early 2020, patients with a diagnosis of cancer were  
78 designated as a particularly vulnerable subgroup of the population. Cancer patients have been reported to be not  
79 only at increased risk of contracting SARS-CoV-2 infections, but also of running a more severe disease course,  
80 with a higher proportion requiring higher levels of intensive care, having a more rapidly evolving disease, and with  
81 increased risk of death. (2) (3) (4) However, as every subspecialised oncologist knows, the term 'cancer'  
82 encompasses a myriad of disease, with a diverse array of primary tumour subtype and stages, affecting a  
83 heterogeneous group of patients of all ages, and which result in very different cancer prognoses and outcomes.  
84 Therefore, labelling all cancer patients as 'COVID-19 vulnerable' is probably neither reasonable nor informative.

85

86 As a consequence of generic advice given to 'COVID-19 vulnerable' members of the population, cancer patients  
87 (of any age, gender, tumour subtype and stage) have been labelled as high risk from COVID-19 and this has led  
88 to sweeping changes in cancer management for all cancer types over the last few months, including abbreviation  
89 of radiotherapy, switching from IV to oral chemotherapy regimens, and the avoidance of immunotherapy. (5) (6)  
90 (7) (8) These changes, perhaps reasonably in an acute pandemic situation, were instigated with very little evidence  
91 to support them. And due to lack of evolving evidence, there has been little attempt to define the individualised risk  
92 for a given patient, taking into account their primary tumour subtype, age and gender.

93

94 We report here, from the UK Coronavirus Cancer Monitoring Project (9), the first analysis of the complex interaction  
95 between patient demographics and tumour subtype, to more accurately estimate the risk of SARS-CoV-2 infection  
96 / COVID-19 in patients with cancer. We describe the clinical outcomes of COVID-19+ cancer patients entered on  
97 the UKCCMP registry, and compare primary cancer subtype prevalence/case fatality rate to the United Kingdom's  
98 (UK) Office for National Statistics (ONS) cancer incidence data.

## 99 **Methods**

### 100 **Study Design and Participants**

101 The UKCCMP database of United Kingdom (UK) cancer patients was set up on the 18<sup>th</sup> of March and has been  
102 designed as a Public Health Surveillance registry for the COVID-19 pandemic. At an institutional level, the entry of  
103 patients on to the registry was approved according to local information governance processes. All patients with  
104 active cancer and who presented to a cancer centre within the UKCCMP network from March 18<sup>th</sup> 2020 with a  
105 positive SARS-CoV-2 test, were eligible for enrolment on the registry. The patients presented for secondary care  
106 review for potential hospitalization and were not part of a proactive surveillance program. Patients with active  
107 cancer were defined as those with metastatic cancer, or those undergoing anti-cancer treatment in any setting  
108 (curative/radical/adjuvant/neoadjuvant) or those treated within the past 12 months with surgery/cytotoxic  
109 chemotherapy/radiotherapy. Data collection is ongoing within the registry but for all patients presented here,  
110 outcomes were monitored up to May 8<sup>th</sup> 2020. This study was conducted in accordance with the Strengthening the  
111 Reporting of Observational studies in Epidemiology (STROBE) statement.  
112

### 113 **Data Collection**

114 Prospective data collection was performed by a pan-UK cancer centre emergency response network set up by the  
115 UKCCMP. All registry patient entries were de-identified at source to ensure that all data is anonymous to  
116 researchers. Data was entered into a Research Electronic Data Capture (REDCap) browser-based metadata  
117 driven electronic data capture (EDC) software system. (10) The secure EDC platform was hosted by the Institute  
118 of Translational Medicine at the University of Birmingham. Patient demographics and cancer features were  
119 obtained from the direct assessment of the Emergency Response Reporting Individual or Local Emergency  
120 Response Reporting Group (ERRI/LERRG) and/or through hospital medical records. In keeping with international  
121 practice, patients were deemed to have SARS-CoV-2 infection if there was a positive Real-Time Reverse  
122 Transcription Polymerase Chain Reaction (RT-PCR) assay test from a throat/nose swab. Patients with a  
123 radiological, clinical diagnosis of SARS-CoV-2, without a positive RT-PCR test were not included in this analysis.  
124 Bronchoalveolar lavage is not recommended in the UK (27). Primary cancer subtype was defined according to  
125 ICD-10 diagnostic codes.  
126

### 127 **Clinical management**

128 Management of cancer patients with COVID-19 was directed by the patient's clinician team without input from the  
129 UK CCMP. They were based on local policies and standard UK clinical practice at the time of this study. Decisions  
130 on ITU admission and ventilation were guided by the UK National Health Service, National Institute of Health and  
131 Care Excellence COVID-19 rapid guidelines (11).  
132

### 133 **UKCCMP data processing and analysis**

134 The data through the REDCap platform was transferred securely through to the Compute and Storage for Life  
135 Science (CaStLeS) infrastructure as part of the Birmingham Environment for Academic Research local Cloud  
136 (BEARCloud) (12) via the Centre for Computational Biology, University of Birmingham. Within CaStLeS, the data  
137 is curated to avoid duplications and errors, then annotated with further information such as geolocation before it  
138 can be analysed and disseminated.  
139

### 140 **Comparator data sources**

141 A historical control dataset was obtained from the UK Office for National Statistics (ONS). Tumour subtype and  
142 demographics analysis utilised the latest release of the "Cancer Registration Statistics, England, 2017" which is  
143 publicly available. (13). This is the latest cancer registration database in England and involves registrations of  
144 patients up to 2017. Cancer registrations in England take years after a given calendar year to reach nationally  
145 validated quality control measures for robustness of analyses due to continuing accrual of registrations.  
146

### 147 **Statistical analysis & Data visualisation**

148 In this study, we report on the cancer patient demographics (primary tumour subtype, age and gender) of those  
149 who contract the SARS-CoV-2 infection and describe their COVID-19 clinical course. We compare these  
150 demographic characteristics with those gleaned for the whole cancer population from the UK Office for National  
151 Statistics (ONS) cancer control dataset. The primary outcome of interest was all-cause inpatient case fatality rate  
152 (during the COVID-19 episode) and this was used for all regression analyses and analyses by tumour subtype.  
153 This included death designated as a direct result of COVID-19 as well as death from any other cause such as  
154 cancer progression and treatment toxicity. Skin cancers were not included in these analyses as they are excluded  
155  
156

157 from the ONS dataset. Patients with an unspecified tumour subtype were also excluded from this analysis. A two-  
158 sided Fisher's exact test was used to compare categorical data from different categories. Multivariable logistic  
159 regression (14) was used to estimate odd ratios and 95% confidence intervals of each defined factor after  
160 adjustment for potential confounders of patient age and gender.

## Results

### *Susceptibility to SARS-CoV-2 Infection*

We are reporting on 1,044 patients with active cancer and a documented SARS-CoV-2 infection/COVID-19 registered in the UKCCMP database with outcomes censored at 8<sup>th</sup> May, 2020. Of this cohort, 595 were men (57.0%) and the median age was 70 years, IQR 60-77. Patients were followed up from the point of COVID-19 diagnosis to either discharge from hospital or death. Mean follow up was 7.8 days (standard deviation 8.2 days).

The demographics and cancer subtype of the COVID-19+ cancer population from the UKCCMP registry were compared with those from the population of cancer patients represented in the ONS cancer census which was used as a historical control group. Compared to the ONS control population of cancer patients, we found that COVID-19+ cancer patients were significantly more likely to be male (57.0% in UKCCMP vs 51.3% in ONS, OR 1.26 95% CI [1.12 to 1.43];  $p=0.0002$ ) but the age distribution of cancer patients who contracted COVID-19 was not significantly different to the ONS cancer control population (median age group 70-79 for both series) (Supp. Figure 1).

We found that certain tumour subtypes were overrepresented in the UKCCMP COVID-19+ patient cohort. Patients with haematological malignancies appeared to be at significantly increased risk, and these included those with leukaemia (OR 2.82 95% CI [2.21 to 3.55];  $p<0.001$ ), myeloma (OR 2.03 95% CI [1.42 to 2.83];  $p<0.001$ ) and lymphomas (OR 1.63 95% CI [1.28 to 2.06];  $p<0.001$ ) (Table 1). In contrast, patients with lung cancer and prostate cancer were relatively underrepresented in the COVID19+ UKCCMP series compared to the control ONS series of cancers. Lung cancer made up 10.7% of the UKCCMP series compared to 13.7% of ONS cases (OR 0.75 95%CI [0.61-0.91];  $p=0.003$ ). Similarly, prostate cancer comprised 11.0% of the UKCCMP series compared to 14.6% of the ONS cohort (OR 0.72 95%CI [0.59-0.88];  $p<0.001$ ).

### *Case fatality rate from COVID-19*

337 of the 1044 COVID-19+ UKCCMP cancer patients died (29.7%), of which the cause of death was recorded as due to COVID-19 in 92.3% ( $n=311$ ). The all-cause case fatality rate in cancer patients following COVID-19 was significantly linked to increasing age, with the case fatality rate in the 40-49, 50-59, 60-69, 70-79 and over 80 groups being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively, and no deaths recorded in the under 40 group (Figure 1, Supp. Figure 2). In addition, the all-cause case fatality rate in cancer patients once they had contracted COVID-19 also appeared to be associated with gender, in males being 0.34 and that in females being 0.23, (OR 1.92 95% CI [1.51 to 2.45],  $p<0.001$ ). We confirmed that advancing age was a significant risk factor for death following COVID-19, with the population of over 70-year olds being over-represented (Supp. Figure 3).

We compared the case fatality rate for each primary tumour subtype in the UK CCMP to a reference, the C15-C26 subtype (digestive organs) as it was the tumour subtype with the central case fatality rate. On univariate analysis we observed a significantly higher risk in patients with prostate cancer (OR 2.14, 95% CI [1.17 to 3.96];  $p=0.014$ ), and leukaemia (OR 2.03, 95% CI [1.04 to 3.97];  $p=0.038$ ) and a significantly lower risk for patients with breast cancer (OR 0.53, 95% CI [0.28 to 1.00];  $p=0.049$ ) and female genital organ cancer (OR 0.36, 95% CI [0.13-0.87];  $p=0.031$ ) (Figure 2, Supp. Figure 4). We then performed a multivariate correction for clinically relevant confounders, age and gender. Compared to the rest of the UKCCMP cohort, patients with leukaemia remained at significantly increased case fatality rate (OR 2.25, 95% CI [1.13 to 4.57];  $p=0.023$ ), (Table 2, Supp. Figure 5). However, after multivariate correction, prostate cancer was no longer significantly associated with increased case fatality rate, and breast and female genital cancers were no longer associated with reduced case fatality rate, highlighting the striking effect of patient age and gender on case fatality rate. Also, on multivariate analysis, we did not find a significantly increased case fatality rate from COVID19 in the lung cancer population (OR 1.41 95%CI [0.75-2.67];  $p=0.285$ ) compared to the rest of the UKCCMP population.

We then undertook a specific detailed analysis of the 227 patients with haematological malignancies who were diagnosed with COVID-19. Compared to the remainder of the UKCCMP cohort (with non-haematological cancers), we found that these patients presented with similar symptoms. (Supp Table 2). However, adjusting for potential confounding variables of age and gender, patients with haematological malignancies were significantly more likely to require high flow oxygen (OR 1.82 95% CI [1.11 to 2.94];  $p=0.015$ ), non-invasive ventilation (OR 2.10 95% CI [1.14-3.76;  $p=0.014$ ]), ITU admission for ventilation (OR 2.73 % CI [1.43 to 5.11];  $p=0.002$ ) and have a severe/critical disease course (OR 1.57 95% CI [1.15 to 2.15];  $p=0.004$ ) (Supp. Table 1). 47.6% of patients with haematological malignancies had received recent chemotherapy within 4 weeks of COVID-19 presentation compared to 29.5% of those with non-haematological cancers (OR 2.15 95% CI [1.57-2.95];  $p<0.0001$ ) (Supp. Table 1). On univariate analysis, recent use of chemotherapy in these patients, was not associated with significantly

220 increased risk compared to those who had no recent chemotherapy use. However, following correction for age and  
221 gender, patients with haematological malignancies who had recent chemotherapy were at increased risk of death  
222 during the COVID-19 associated admission (OR 2.09 95% CI [1.09 to 4.08]; p=0.028).

223 **Discussion**

224  
225 During the COVID-19 pandemic, there has been a dual fold effect on cancer practice. There have been radical  
226 changes to the treatment of patients already diagnosed with cancer, including cessation/interruptions of active  
227 therapies and delays in surgery. (15) (16) There has also been a concerning dramatic reduction in oncology  
228 referrals to secondary care in the United Kingdom. (17) There is likely to have been a number of factors contributing  
229 to this observation. However, a perception of excessive vulnerability of all cancer patients or futility of cancer  
230 treatments in the context of a pandemic is one proposed cause. Unchallenged, this is likely to lead to  
231 decreased/delayed cancer presentations or referrals and expose a significant proportion of the population to  
232 considerable harm beyond COVID-19. At the inception of our study, the largest study of cancer patients who  
233 developed COVID-19 was a 105 patient cohort study from China and the authors reported high mortality rates from  
234 COVID-19 in patients with haematological malignancies, lung cancer and patients with metastatic cancer. (18)  
235 However, the small size of that cohort and therefore the very small numbers of patients with each tumour type  
236 within it, made it difficult to be conclusive about these findings. For all cancer patients, in any situation, whether we  
237 are attempting cure or trying to palliate symptoms and extend life, there is a fine balance between potential benefits  
238 and risks of treatment. Therefore, it is critical that we do properly identify the individualised risk of harm from COVID-  
239 19 for each cancer patient, rather than treating them as a homogeneous 'vulnerable' population, and that we put  
240 that risk into the context of their individual cancer prognosis.

241  
242 Risk of severe morbidity and eventual mortality from SARS-CoV-2 infection for any individual in the population is  
243 driven by two key factors, baseline *viral susceptibility* and the ensuing *COVID-19 phenotype*. *Viral susceptibility* is  
244 a dynamic interplay between specific exposure and potential host predisposition/vulnerability to infection. In cancer  
245 patients, there may be a particular host predisposition/vulnerability either as a result of having a dysregulated  
246 immune response skewing it away from an ability to fight viral infection; or indeed cancer-induced damage to  
247 epithelial membranes. The *COVID-19 phenotype* experienced by a cancer patient is likely to be a complex interplay  
248 of several factors, including patient demographics, other co-morbidities, cancer phenotype and effects of cancer  
249 treatment, as well as the intensity of COVID-19 treatment that the individual patient then receives.

250  
251 The UKCCMP has collected primary tumour type and demographic data on over 1000 patients with cancer who  
252 contracted SARS-CoV-2 and developed COVID-19, and analysed this not only within the UKCCMP population, but  
253 also compared it with ONS data from the general cancer population. This has allowed us to segregate the cancer  
254 population by risk, considering the already known risk factors for COVID-19 such as gender (males at higher risk  
255 than females) and advancing age.

256  
257 In this study, we have found that both *viral susceptibility* and the *COVID-19 phenotype* are influenced by primary  
258 tumour subtype. Patients with haematological malignancies (leukaemias, lymphomas and myelomas) appear to  
259 have an *a priori* increased viral susceptibility, and to be at greater risk of having a more severe *COVID-19 clinical*  
260 *phenotype*, to require more intensive supportive interventions, and to suffer an elevated risk of death. Patients with  
261 the haematological codes (C86, C88, C96) had the highest viral susceptibility. The reasons for this are unclear and  
262 likely reflects the small number of patients involved and stochastic effects (n=29), but it is possible that these  
263 haematological subtypes may have a specific immunological susceptibility to COVID-19 infection. On multivariate  
264 analysis, patients with leukaemia still had a significantly higher risk of death related to COVID-19, considering age  
265 and gender. The increased case fatality rate in haematological malignancies is similar to that observed in a pre-  
266 print article from the United Kingdom (19) and Chinese cohorts (20) (21), but in contrast to a recent American  
267 cohort study (22) which does not suggest increased mortality in this group.

268  
269 Recent large COVID-19 cancer cohorts of predominantly solid organ tumours have identified no significant excess  
270 mortality risk from recent chemotherapy (16) (22). In this study, we have identified that in haematological  
271 malignancies, following multivariable analysis, risk does appear to be heightened by recent (within 4 weeks) or  
272 current chemotherapy. It is possible that haematological patients undergoing chemotherapy may be responsible  
273 for observations from other cohorts (23).

274  
275 There are likely to be a number of possible reasons for these observations. The immunological disruption *per se*  
276 observed in patients with leukaemia and the use of intensely myelosuppressive regimes may result in a devastating  
277 combination of risk, both in terms of the likelihood of initial SARS-CoV-2 infection and its ability to gain a foothold  
278 in the host and also in terms of the downstream disease course and likelihood of severe consequences such as  
279 cytokine storm and significant multiorgan failure. Further work is necessary in larger haematological cancer cohorts  
280 to have the power to discern the relative importance of these factors with more certainty.

281  
282 Contrary to the findings from the Chinese series and data from a European registry (24), we found that patients  
283 with lung cancer were relatively underrepresented in the UKCCMP cohort compared to the ONS data. In addition,  
284 once COVID-19 was established in lung cancer patients, we found no significantly increased case fatality rate  
285 compared to the general COVID19+ cancer population within UKCCMP, suggesting that lung cancer patients are  
286 not a specifically vulnerable group. There are likely to be a number of reasons for this difference in findings. Firstly,  
287 there are methodological differences, with this study comparing lung cancer cases to a cancer population rather  
288 than a non-cancer population. Secondly, there may now be more effective shielding of lung cancer patients at an  
289 early stage in the pandemic when they were designated as vulnerable. Thirdly, lung cancer is the commonest  
290 cancer in China, and hence would be overrepresented in their COVID-19+ cancer patient population and finally the  
291 European registry does not use a controlled group and this highlights the importance of our intra population-  
292 controlled studies.

293  
294 Prostate cancer patients were relatively underrepresented in the UKCCMP cohort again compared to ONS data,  
295 again perhaps due to shielding, or perhaps due to a reluctance to bring this cohort of patients to hospital even if  
296 they developed COVID symptoms. In terms of risk of death once COVID-19 was established, initially the prostate  
297 cancer group of patients did appear to be an increased case fatality rate, but multivariate analysis that actually their  
298 risk was no greater than the rest of the COVID-19+ cancer population in UKCCMP, reflecting again the importance  
299 of gender more specifically as factor.

300  
301 Patients with breast cancers or malignancies of the female genital tract appeared to be at much lower risk, either  
302 of contracting or of dying from COVID-19. However multivariate analysis again demonstrated that this protection  
303 was by virtue of the patients being female, rather than an inherently lower risk tumour per se. (25) (26)  
304

305 Overall, in interpreting these data, and putting them into context, our diverse subpopulations of cancer patients are  
306 at equally diverse risks of SARS-CoV-2 infection and of suffering a severe COVID-19 phenotype upon infection.  
307 This needs to be borne in mind when deciding on the level of shielding cancer patients require, depending on the  
308 likely prognosis from their cancer. For example, many patients may take the risk of COVID-19 and see their  
309 grandchildren, rather than spend the last two months of their life alone. Exposure to SARS-CoV-2 should be  
310 minimised for all cancer patients through judicious and contextualised use of social/clinical isolation measures but  
311 also perhaps through measures such as regular SARS-CoV-2 infection screening of their clinical and home  
312 contacts whilst continuing treatment with optimal anti-cancer treatment. However, enhanced strategies to prevent  
313 viral transmission must be employed in patients with haematological conditions, particularly where the risk of not  
314 proceeding with systemic treatment is high. For all cancer types, risk is lower in younger patients and those of  
315 female sex, reinforcing the importance of gender and age as determinants of SARS-CoV-2 / COVID-19 risk.

316  
317 This paper allows oncologists and other healthcare professionals to more effectively risk stratify cancer patients  
318 and to counsel them accordingly during this unprecedented time for oncological care. We note some of the  
319 limitations of this analysis. Our analyses are based on symptomatic cancer patients who seek help from cancer  
320 centres. Therefore, the cohort may not be entirely representative of all patients with cancer, and patients may  
321 therefore be more likely to be those under ongoing oncological follow-up, and less likely to be patients on an end  
322 of life pathway or from nursing homes/hospices. There may be limitations in our comparison to the ONS control  
323 population of cancer patients. In this study, we report on patients with "Active Cancer" whereas the ONS control  
324 population is a historical control, consisting of all patients with a diagnosis of cancer up to 2017 and therapies in  
325 oncology and the spectrum of disease may have changed. Therefore, more contemporary analyses, in diverse  
326 population datasets will need to be performed. In addition, as discussed, there is a low admission rate of cancer  
327 patients to ITU, which is likely to impact on COVID-19 outcomes in cancer patients in the United Kingdom (16).  
328 Furthermore, we have only performed multivariable correction for age and sex, which appear to be the primary  
329 drivers of case fatality. Finally, this analysis has been performed without an a priori power calculation in order to  
330 facilitate timely dissemination of results.

331  
332 However, rates of COVID-19 in cancer patients remain thankfully low overall and the age distribution of patients in  
333 the UKCCMP reflects the age distribution in the ONS dataset suggesting that our comparator population is as  
334 appropriate as possible at this stage.

335  
336 Despite these noted limitations, our study is unique in comparing the dataset to an accurate cancer population  
337 control dataset. Morbidity and case fatality rate from COVID-19 (once established) in UK cancer patients attending  
338 hospital is relatively high, particularly in those with haematological malignancies and advancing age, but not all

339 cancer patients are affected equally which is a very important finding. The UKCCMP will continue to monitor risks  
340 to patients following the end of the first UK pandemic peak, provide early warning of further pandemic peaks and  
341 provide timely and meaningful information to the cancer community to enable the highest quality of cancer care to  
342 continue.

	UKCCMP cases (%)	ONS cases (%)	Odds Ratio (95% CI)	p value
<b>Patient Features</b>				
-Male	595 (57.0%)	145034 (51.3%)	1.26 (1.12-1.43)	0.0002
-Female	445 (42.6%)	137844 (48.7%)		
-Other	4 (0.4%)	0 (0.0%)		
-Median age/years	70	NA*		
<b>Cancer Subtype</b>				
-Breast (C50-C50)	143 (13.7%)	46109 (16.3%)	0.82 (0.68-0.98)	0.026
-Colorectal (C18-C21)	124 (11.9%)	36039 (12.7%)	0.93 (0.76-1.12)	0.456
-Prostate (C61)	114 (11.0%)	41200 (14.6%)	0.72 (0.59-0.88)	<0.001
-Lung (C34)	111 (10.7%)	38878 (13.7%)	0.75 (0.61-0.91)	0.003
-Digestive organs (non-colorectal) (C15-C26)	95 (9.1%)	30096 (10.6%)	0.84 (0.68-1.04)	0.118
-Urinary tract (C64-C68)	77 (7.4%)	19333 (6.8%)	1.09 (0.85-1.38)	0.46
-Female genital organs (C51-C58)	56 (5.4%)	17969 (6.4%)	0.84 (0.63-1.10)	0.226
-Lip, oral cavity and pharynx (C00-C14)	33 (3.2%)	7558 (2.7%)	1.19 (0.82-1.69)	0.334
-Central nervous system (C69-C72)	25 (2.4%)	5038 (1.8%)	1.36 (0.87-2.02)	0.127
-Mesothelial and soft tissue (C45-C49)	16 (1.5%)	4682 (1.7%)	0.93 (0.53-1.52)	0.903
-Respiratory and intrathoracic organs (not lung) (C30-C39)	11 (1.1%)	2780 (1.0%)	1.08 (0.53-1.94)	0.752
-Bone and articular cartilage (C40-C41)	4 (0.4%)	376 (0.1%)	2.90 (0.78-7.50)	0.053
-Male genital organs (C60-C63)	4 (0.4%)	2435 (0.9%)	0.44 (0.12-1.14)	0.126
-Endocrine glands (C73-C75)	4 (0.4%)	3374 (1.2%)	0.32 (0.09-0.82)	0.01
-Lymphoma (C81-C85)	79 (7.6%)	13537 (4.8%)	1.63 (1.28-2.06)	<0.001
-Leukaemia (C91-C95)	79 (7.6%)	8018 (2.8%)	2.82 (2.21-3.55)	<0.001
-Myeloma (C90)	37 (3.6%)	5033 (1.8%)	2.03 (1.42-2.83)	<0.001
-Other Haematological (C86, C88, C96)	29 (2.8%)	423 (0.1%)	19.14 (12.59-28.05)	<0.001

Table 1: Demographics and tumour subtype representation in the UKCCMP Covid-19 cohort compared to the ONS cancer control population. \* Individual ages not available in dataset. Univariate analysis was performed, p values were determined by Fisher exact test and unadjusted for age and gender.

343  
344  
345  
346

Tumour subtype	No. of Deaths	Case-fatality rate	Univariate odds ratio (95% CI)	p value	Multivariable adjusted odds ratio (95% CI)	p value
Prostate (C61)	49	0.43	2.14 (1.17-3.96)	0.014	1.09 (0.51-2.33)	0.824
Lung (C34)	43	0.387	1.62 (0.89-3.00)	0.118	1.41 (0.75-2.67)	0.285
Mesothelial and soft tissue (C45-C49)	6	0.375	1.18 (0.37-3.51)	0.772	1.52 (0.43-5.30)	0.505
Urinary tract (C64-C68)	23	0.299	1.08 (0.54-2.13)	0.834	0.87 (0.41-1.81)	0.715
Colorectal (C18-C21)	35	0.282	1.03 (0.56-1.90)	0.934	0.85 (0.44-1.64)	0.627
Central nervous system (C69-C72)	7	0.28	1.15 (0.39-3.18)	0.797	1.87 (0.57-6.05)	0.292
Respiratory organs (C30-C39)	3	0.273	0.84 (0.17-3.29)	0.813	0.96 (0.18-4.10)	0.954
Lip, oral cavity and pharynx (C00-C14)	8	0.242	0.75 (0.28-1.85)	0.542	0.77 (0.25-2.27)	0.644
Breast (C50)	26	0.182	0.53 (0.28-1.00)	0.049	0.97 (0.40-2.52)	0.942
Female genital organs (C51-C58)	7	0.125	0.36 (0.13-0.87)	0.031	0.79 (0.24-2.63)	0.704
<i>Myeloma (C90)</i>	16	0.432	1.85 (0.81-4.22)	0.142	1.65 (0.71-3.85)	0.241
<i>Leukaemia (C91-C95)</i>	33	0.418	2.03 (1.04-3.97)	0.038	2.25 (1.13-4.57)	0.023
<i>Lymphoma (C81-C85)</i>	25	0.316	1.60 (0.80-3.19)	0.184	1.72 (0.81-3.68)	0.156
<i>Other Haematological (C86, C88, C96)</i>	7	0.241	0.81 (0.28-2.12)	0.675	0.81 (0.26-2.33)	0.702
Digestive organs (C15-C17, C22-C26)	28	0.295	Reference	Reference	Reference	Reference

Table 2: All-cause case fatality rate following COVID-19 by tumour subtype, before and after age and sex correction. Odds ratio was performed relative to Digestive organs (non-colorectal) (C15-C26). Multivariable corrections were performed correcting for patient age and gender.

347  
348  
349  
350




Figure 1: Age and risk of all-cause case fatality rate of patients following a presenting with COVID-19 in the UKCCMP cohort.

352  
353  
354  
355  
356




Figure 2: Heatmap demonstrating case fatality rate following a COVID-19 presentation, broken down by tumour subtype, age and gender. Grey bars represent where number of cases were less than 4.

357  
358  
359  
360

361 SUPPLEMENTARY METHODS

362

363 **Statistical analysis & Data visualisation**

364 Analyses were performed in R version 3.6.3 utilising the glm() (family = binomial(link = "logit")) and fisher.test()  
365 functions, respectively. Data processing and visualisation utilised R (version 3.6.3) packages including broom,  
366 dplyr, forestplot, ggplot2, ggsci, pheatmap, RColorBrewer, robustbase and viridis. Data subsetting was performed  
367 using the subset() function of 'robustbase' and data reshaping for visualisation involved the use of the tidy() function  
368 of 'broom', and group\_by() and melt() functions of 'dplyr'. Functions from the ggplot2 R package were used to  
369 generate multiple plots including barplots (geom\_bar) and lineplots (geom\_line). The pheatmap() and forestplot()  
370 functions of the 'pheatmap' and 'forestplot' R packages was also used to generate the heatmap and forest plots,  
371 respectively.


372

373 **Data Collection**

374 Prospective data collection was performed by the pan-UK cancer centre emergency response network. Case  
375 reporting was led by a COVID-19 Emergency Response Reporting Individual (ERRI), supported by a Local  
376 Emergency Response Reporting Group (LERRG) at each centre. The UKCCMP encouraged all local reporting  
377 sites to enter data in a real time basis, as soon as a positive SARS-CoV-2 test had been identified. The data  
378 fields were then re-updated as soon as treatment and outcomes had been identified. The ERRI was a  
379 trained/training oncologist who did data review, annotation and entry. In a small number of centres, data entry  
380 was performed by data managers but with direct oversight by the ERRI. This secure EDC platform is hosted by  
381 the Institute of Translational Medicine at the University of Birmingham.


382

383  
384




385  
386  
387  
388

Supplementary Figure 1. Stacked bar chart showing age distribution of cancer patients in the UKCCMP who had contracted SARS-CoV-2 and ONS cancer control population.




389  
390  
391

Supplementary Figure 2. Forest plot showing distribution of age groups of cancer patients who died in the UKCCMP and case fatality rates. Odds ratio are relative to the UK CCMP population.




392  
393  
394  
395

Supplementary Figure 3: Forest plot showing distribution of age groups of patients who died in the UKCCMP relative to the age distribution of the ONS cancer control population.



396  
397  
398  
399  
400

Supplementary Figure 4: Case fatality rate of patients following a presenting with COVID-19 in the UKCCMP cohort, assessed by tumour subtype.



401  
402  
403  
404  
405

Supp Figure 5. Waterfall plot showing risk of death for each tumour subtype following COVID-19 compared to other subtypes (reference), before and after age and sex correction multivariable correction. \* denotes statistical significance of  $p$  adjusted, where  $p < 0.05$ .

	Haematological malignancies (n=227)	Non-haematological malignancies (n=817)	Univariate analysis		Multivariable adjusted analysis	
			Odds Ratio (CI)	p value	Odds Ratio (CI)	p value
<b>Patient features</b>						
- Male	148 (65.2%)	447 (54.7%)	1.53 (1.13-2.09)	0.006	1.58 (1.16-2.16)	0.004
- Female	79 (34.8%)	366 (44.8%)				
- Other	0 (0.0%)	4 (0.5%)				
- Median age/years (std)	69 (14.16)	70 (13.09)		0.034		
<b>Co-morbidities</b>						
- Cardiovascular disease	21 (9.3%)	124 (15.2%)	0.56 (0.34-0.91)	0.023	0.62 (0.36-1.01)	0.065
- COPD	7 (3.1%)	73 (8.9%)	0.32 (0.13-0.66)	0.005	0.35 (0.14-0.72)	0.009
- Diabetes	33 (14.5%)	145 (17.7%)	0.79 (0.51-1.18)	0.262	0.78 (0.50-1.17)	0.243
- Hypertension	60 (26.4%)	283 (34.6%)	0.66 (0.47-0.92)	0.017	0.68 (0.47-0.97)	0.033
- None	52 (22.9%)	153 (18.7%)	1.32 (0.91-1.90)	0.138	1.31 (0.87-1.96)	0.189
- No data	39 (17.2%)	136 (16.6%)				
<b>Smoking status</b>						
- Current smoker	7 (3.1%)	38 (4.7%)	0.99 (0.39-2.17)	0.984	0.77 (0.30-1.74)	0.558
- Ex-smoker	32 (14.1%)	234 (28.6%)	0.59 (0.37-0.94)	0.028	0.63 (0.38-1.03)	0.067
- Never smoker	52 (22.9%)	218 (26.7%)	1.66 (1.06-2.63)	0.027	1.67 (1.04-2.70)	0.035
- No data	136 (59.9%)	327 (40.0%)				
<b>Patient outcome</b>						
- Death (all cause)	82 (36.1%)	237 (29.0%)	1.61 (1.15-2.24)	0.005	1.74 (1.21-2.48)	0.002
- Death (COVID-19)	80 (35.2%)	215 (26.3%)	1.77 (1.27-2.48)	0.001	1.93 (1.35-2.77)	<0.001
- Death (Cancer)	1 (0.4%)	18 (2.2%)	0.21 (0.01-1.02)	0.129	0.22 (0.01-1.06)	0.138
- Death (other)	1 (0.4%)	4 (0.5%)	0.96 (0.05-6.54)	0.972	1.12 (0.06-7.79)	0.923
- Hospitalised	5 (2.2%)	36 (4.4%)	0.52 (0.18-1.23)	0.178	0.53 (0.18-1.26)	0.192
<b>Cancer treatment within 4 weeks</b>						
- Chemotherapy	108 (47.6%)	241 (29.5%)	2.17 (1.60-2.93)	<0.0001	2.15 (1.57-2.95)	<0.0001
- Immunotherapy	0 (0.0%)	39 (4.8%)	0.00 (0.00-2.90E+07)	0.9815	0.00 (0.00-3.17E+07)	0.9813
- Radiotherapy	2 (0.9%)	84 (10.3%)	0.08 (0.01-0.25)	0.0004	0.07 (0.01-0.24)	0.0003
- Surgery	0 (0.0%)	36 (4.4%)	0.00 (0.00-8.99E+07)	0.9816	0.00 (0.00-1.39E+08)	0.9816
- Targeted therapy	26 (11.5%)	65 (8.0%)	1.49 (0.91-2.39)	0.1018	1.45 (0.87-2.33)	0.1397
<b>COVID-19 Symptoms</b>						
- Chills	9 (4.0%)	23 (2.8%)	1.49 (0.64-3.16)	0.324	1.45 (0.62-3.11)	0.357
- Corzylal symptoms	13 (5.7%)	47 (5.8%)	1.04 (0.53-1.90)	0.911	1.03 (0.52-1.90)	0.931
- Cough	93 (41.0%)	381 (46.6%)	0.83 (0.60-1.14)	0.255	0.82 (0.59-1.13)	0.217
- Diarrhoea	26 (11.5%)	63 (7.7%)	1.63 (0.99-2.62)	0.05	1.67 (1.01-2.70)	0.041
- Fatigue	46 (20.3%)	150 (18.4%)	1.19 (0.81-1.73)	0.359	1.22 (0.83-1.77)	0.307
- Fever	133 (58.6%)	450 (55.1%)	1.34 (0.96-1.90)	0.091	1.26 (0.89-1.79)	0.191
- Headache	15 (6.6%)	28 (3.4%)	2.09 (1.07-3.94)	0.026	2.11 (1.07-4.00)	0.026
- Myalgia	18 (7.9%)	60 (7.3%)	1.13 (0.64-1.93)	0.654	1.15 (0.64-1.97)	0.623
- Nausea and/or Vomiting	8 (3.5%)	43 (5.3%)	0.68 (0.29-1.40)	0.332	0.70 (0.30-1.45)	0.372
- Shortness of breath	84 (37.0%)	324 (39.7%)	0.95 (0.69-1.30)	0.734	0.92 (0.66-1.27)	0.61
- Sore throat	9 (4.0%)	32 (3.9%)	1.05 (0.47-2.16)	0.891	0.98 (0.43-2.04)	0.964
- Asymptomatic	5 (2.2%)	39 (4.8%)	0.47 (0.16-1.09)	0.113	0.50 (0.17-1.18)	0.152
- No data	35 (15.4%)	99 (12.1%)				
<b>COVID-19 Severity Score</b>						
- severe/critical	119 (52.4%)	339 (41.5%)	1.53 (1.13-2.06)	0.006	1.57 (1.15-2.15)	0.004
- mild	103 (45.4%)	448 (54.8%)				
- No data	5 (2.2%)	30 (3.7%)				
<b>COVID-19 treatment</b>						
- Antibiotics	145 (63.9%)	495 (60.6%)	1.35 (0.93-2.00)	0.12	1.35 (0.92-2.00)	0.129
- Fluids	86 (37.9%)	247 (30.2%)	1.52 (1.10-2.11)	0.012	1.54 (1.10-2.14)	0.011
- High Flow Oxygen (HFO)	29 (12.8%)	61 (7.5%)	1.89 (1.16-3.01)	0.009	1.82 (1.11-2.94)	0.015
- ITU + Ventilation	19 (8.4%)	25 (3.1%)	3.00 (1.60-5.57)	0.001	2.73 (1.43-5.11)	0.002
- ITU - Ventilation	7 (3.1%)	12 (1.5%)	2.19 (0.81-5.54)	0.104	2.16 (0.78-5.54)	0.118
- Non-invasive Ventilation	19 (8.4%)	35 (4.3%)	2.11 (1.16-3.75)	0.012	2.10 (1.14-3.76)	0.014
- Oxygen	99 (43.6%)	310 (37.9%)	1.38 (1.00-1.90)	0.054	1.41 (1.01-1.96)	0.044
- None	26 (11.5%)	134 (16.4%)	0.67 (0.42-1.04)	0.083	0.65 (0.41-1.02)	0.071
- No data	40 (17.6%)	128 (15.7%)				

406 Supp. Table 1: Univariate and multivariate analyses of differences in patient demographics/symptoms/cancer treatments and clinical  
407 course of haematological vs. non-haematological malignancies. Univariate analysis was conducted with presence compared to absence  
408 (reference for each category) in haematological malignancies vs. non-haematological malignancies. Multivariate analyses were  
409 conducted corrected for patient age and sex.

410 **Acknowledgements**

411 The authors thank the patients, their families, oncologists, acute physicians and healthcare staff working tirelessly  
412 on the frontlines of the COVID-19 pandemic.

413  
414  
415 We would like to thank all members of the UKCCMP reporting network and ERRIs for their hard work in  
416 contributing data at a challenging time:  
417

418 Michael Aggie, Akinfemi Akingboye, Mohammed Alihilali, Angelos Angelakas, Iris Anil, Sarah Ayers, Craig  
419 Barrington, Jane Barrett, Mark Baxter, Ahmed Bedair, Sarah Benafif, James Best, Madhumita Bhattacharyya,  
420 Stephen Booth, Sean Brown, Victoria Brown, Clair Brunner, Emma Burke, Ruth Board, Rachel Bolton, Helen  
421 Bowyer, Hayley Boyce, Lauren Cammaert, Emma Cattell, Joseph Chacko, Olivia Chan, Neha Chopra, Mahbuba  
422 Choudhury, Ryan Claydon, Lucy Cook, Ellen Copson, Pippa Corrie, Stephanie Cornthwaite, Nicola Cox, Jamie  
423 D'Costa, Sarah Derby, Louise Devereaux, Yvette Drew, Caroline Dobeson, Saoirse Dolly, Philip Earwaker, Leonie  
424 Eastlake, Shawn Ellis, Laura Feeney, Ana Ferreira, Claire Fuller, Myria Galazi, Abigail Gault, Aisha Ghaus, Duncan  
425 Gilbert, Robert Goldstein, Paul Greaves, Clare Griffin, Simon Grumett, Julia Hall, Peter Hall, Madeleine Hewish,  
426 Stephen Hibbs, Helen Hollis, Francesca Holt, Laura Horsley, Zoe Hudson, Jack Illingworth, Rema Jyothirmayi,  
427 Sangary Kathirgamakarthisgeyan , Bartlomiej Kurec, Amy Kwan, Sin Lau, Siow Ming Lee, Pauline Leonard, Sarah  
428 Lowndes, Annet Madhan, Samah Massalha, Alison Massey, Alec Maynard, Hayley McKenzie, Agnieszka Michael,  
429 Ali Abdulnabi Mohamed, Sam Moody, Leena Mukherjee, Daniel Muller, Piangfan Naksukpaiboon, Jilian Noble,  
430 Roderick Oakes, Paul Oats, Diego Ottaviani, Shafali Parikh, Alexander Pawsey, Ying Ying Peng, Annet Pillai,  
431 Ashley Poon-King, Sian Pugh, Taslima Rabbi, Paul Ramage, Emily Renninson, Tim Robinson, Tom Roques,  
432 Michael Rowe, Joseph Sacco, Rebecca Sargent, Martin Scott-Brown, Christopher Scrase, Simon Shamas,  
433 Heather Shaw, Rachel Sharkey, Omar Sheikh, Rohan Shotton, Fiona Smith, Christopher Sng, Gehan Soosaipillai,  
434 Chrissie Thirlwell, Caroline Usbourne, Sophia Wong, Victoria Woodcock, Anjui Wu, Simon Wyatt.

435

436

437 **Author Contributions**

438 LYWL, JBC, SB, RA, VC, HMC, DJH, DK, AJXL, ACOB, CP, KP, AB, GM, and RK were involved in the study  
439 design; LYWL, JBC, MWF, SG, AJXL, RL, NM, TND, ACOB, TP, KP, OT, GM, RK and UKCCMP were involved  
440 in the data collection; LYWL, JBC, TS, RA, VB, NAC, VC, HMC, PE, AG, SH, DJH, AJXL, HM, CPM, ACOB, CP,  
441 EP, KP, ASP, AS, CV, VW, GM and RK were involved in data acquisition and management; LYWL, JBC, SB, TS,  
442 AB, GM, and RK were involved in data analysis and interpretation; LYWL, JBC, TS, SB, AB, GM, and RK were  
443 involved in manuscript writing; and RK made the decision to submit.

444

445

446 **Declaration of interest**

447

448 ACOB has received grant support from Roche, Bristol-Myers-Squibb, Eli Lilly, Novartis and UCB Pharma, and  
449 personal fees from Roche, Bristol-Myers-Squibb, all outside the submitted work. NM has advisory board roles for  
450 Pfizer, Roche, Boehringer Ingelheim; received speakers' bureau from Merck, Pfizer and Roche, all outside the  
451 submitted work. TND has received personal fees from Astra Zeneca, Amgen, Bayer, BMS, Boehringer Ingelheim,  
452 MSD, Lilly, Novartis, Pfizer, Roche, Takeda and non-financial support from BMS, MSD, Roche and Takeda, all  
453 outside the submitted work. The other authors have nothing to disclose.

454

455 REFERENCES

- 456
- 457 1. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. [cited 2020  
458 Apr 22]. Available from: [https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))  
459 [coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
- 460 2. Liang W, Guan W, Chen R, Wang W, Jianfu Li, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a  
461 nationwide analysis in China. *Lancet Oncol*. 2020 Mar 1;21(3):335–7.
- 462 3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care  
463 Hospital in Wuhan, China. *JAMA Oncol* [Internet]. 2020 Mar 25 [cited 2020 Apr 8]; Available from:  
464 <https://jamanetwork.com/journals/jamaoncology/fullarticle/2763673>
- 465 4. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do Patients with Cancer Have a  
466 Poorer Prognosis of COVID-19? An Experience in New York City. *Ann Oncol* [Internet]. 2020 Apr 21 [cited  
467 2020 Apr 25];0(0). Available from: [https://www.annalsofncology.org/article/S0923-7534\(20\)39303-](https://www.annalsofncology.org/article/S0923-7534(20)39303-0/abstract)  
468 [0/abstract](https://www.annalsofncology.org/article/S0923-7534(20)39303-0/abstract)
- 469 5. ESMO. Cancer Patient Management During the COVID-19 Pandemic [Internet]. [cited 2020 Apr 25].  
470 Available from: <https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic>
- 471 6. Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer [Internet].  
472 [cited 2020 May 18]. Available from: <https://www.england.nhs.uk/coronavirus/publication/specialty-guides/>
- 473 7. Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the  
474 SARS-CoV-2 pandemic: primum non nocere. *ESMO Open*. 2020;5(2).
- 475 8. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide  
476 Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the  
477 Coronavirus Disease 2019 Era - European Urology [Internet]. [cited 2020 Jun 13]. Available from:  
478 [https://www.europeanurology.com/article/S0302-2838\(20\)30324-9/fulltext](https://www.europeanurology.com/article/S0302-2838(20)30324-9/fulltext)
- 479 9. Anil I, Arnold R, Benkwitz-Beford S, Branford S, Campton N, Cazier J-B, et al. The UK Coronavirus Cancer  
480 Monitoring Project: protecting patients with cancer in the era of COVID-19. *Lancet Oncol* [Internet]. 2020 Apr  
481 15 [cited 2020 Apr 16];0(0). Available from: [https://www.thelancet.com/journals/lanonc/article/PIIS1470-](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30230-8/abstract)  
482 [2045\(20\)30230-8/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30230-8/abstract)
- 483 10. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture  
484 (REDCap)—A metadata-driven methodology and workflow process for providing translational research  
485 informatics support. *J Biomed Inform*. 2009 Apr 1;42(2):377–81.
- 486 11. COVID-19 rapid guideline: critical care in adults. 2020;13.
- 487 12. Thompson SJ, Thompson SEM, Cazier J-B. CaStLeS (Compute and Storage for the Life Sciences): a  
488 collection of compute and storage resources for supporting research at the University of Birmingham. 2019  
489 Jun 20 [cited 2020 Apr 8]; Available from: <https://zenodo.org/record/3250616#.Xo2MA27TWvg>
- 490 13. Cancer registration statistics, England - Office for National Statistics [Internet]. [cited 2020 Apr 29]. Available  
491 from:  
492 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletin](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017)  
493 [s/cancerregistrationstatisticsengland/2017](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017)
- 494 14. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per  
495 variable in logistic regression analysis. *J Clin Epidemiol*. 1996 Dec;49(12):1373–9.
- 496 15. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical  
497 recovery plans. *BJS Br J Surg* [Internet]. [cited 2020 Jun 13];n/a(n/a). Available from:  
498 <https://bjssjournals.onlinelibrary.wiley.com/doi/abs/10.1002/bjs.11746>
- 499 16. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Kerr R, Middleton G. COVID-19 mortality in patients with  
500 cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *The Lancet* [Internet].  
501 2020 May 28 [cited 2020 Jun 9];0(0). Available from:  
502 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31173-9/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31173-9/abstract)

- 503 17. Fall in cancer referrals 'could later flood NHS'. BBC News [Internet]. 2020 Apr 23 [cited 2020 May 10];  
504 Available from: <https://www.bbc.com/news/uk-scotland-52393073>
- 505 18. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-  
506 COV-2: a multi-center study during the COVID-19 outbreak. *Cancer Discov.* 2020 Apr 28;
- 507 19. Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors  
508 associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult  
509 NHS patients. *medRxiv.* 2020 May 7;2020.05.06.20092999.
- 510 20. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk  
511 factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective,  
512 cohort study. *Lancet Oncol* [Internet]. 2020 May 29 [cited 2020 Jun 13];0(0). Available from:  
513 [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(20\)30310-7/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30310-7/abstract)
- 514 21. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers.  
515 *Leukemia.* 2020 Jun;34(6):1637–45.
- 516 22. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19  
517 on patients with cancer (CCC19): a cohort study. *The Lancet* [Internet]. 2020 May 28 [cited 2020 Jun  
518 13];0(0). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31187-  
519 9/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31187-9/abstract)
- 520 23. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated  
521 with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort  
522 study. *Lancet Oncol* [Internet]. 2020 May 29 [cited 2020 Jun 13];0(0). Available from:  
523 [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(20\)30309-0/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30309-0/abstract)
- 524 24. Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with  
525 thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. *Lancet*  
526 *Oncol* [Internet]. 2020 Jun 12 [cited 2020 Jun 14];0(0). Available from:  
527 [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(20\)30314-4/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30314-4/abstract)
- 528 25. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-  
529 CoV-2 in the Icelandic Population. *N Engl J Med.* 2020 Apr 14;0(0):null.
- 530 26. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in  
531 China. *N Engl J Med.* 2020 Apr 30;382(18):1708–20.
- 532 27. COVID-19: information for the respiratory community | British Thoracic Society | Better lung health for all  
533 [Internet]. [cited 2020 Jun 13]. Available from: [https://www.brit-thoracic.org.uk/about-us/covid-19-information-  
534 for-the-respiratory-community/](https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community/)
- 535